Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544047 | 1.00 | SCN9A (0.42) | SCN9APDE10AGSK3BCCNB2CDK1 | |
| SCHEMBL25428812 | 0.89 | PDE10A (0.38) | SCN9APDE10AMETAP2 | |
| SCHEMBL25433941 | 0.88 | PDE10A (0.35) | SCN9APDE10AGSK3BCCNB2CDK1 | |
| SCHEMBL25952320 | 0.86 | SCN9A (0.44) | SCN9ASCN5A | |
| SCHEMBL30544057 | 0.86 | SCN9A (0.44) | SCN9ASCN5A | |
| SCHEMBL25427800 | 0.86 | SCN9A (0.39) | SCN9APDE10AMETAP2KCNH2 | |
| SCHEMBL25431565 | 0.82 | GSK3B (0.39) | SCN9APDE10AGSK3BCCNB2CDK1 | |
| SCHEMBL25429484 | 0.81 | SCN8A (0.43) | SCN9ASCN5A | |
| SCHEMBL25952586 | 0.78 | PDE10A (0.34) | PDE10AGSK3BPRKCBKCNH2 | |
| SCHEMBL25430926 | 0.78 | SCN9A (0.37) | SCN9AMETAP2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |